ANAB (AnaptysBio) Accounts Payable & Accrued Expense : $33.3 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Accounts Payable & Accrued Expense?

AnaptysBio's quarterly accounts payable & accrued expense increased from Sep. 2024 ($34.1 Mil) to Dec. 2024 ($35.1 Mil) but then declined from Dec. 2024 ($35.1 Mil) to Mar. 2025 ($33.3 Mil).

AnaptysBio's annual accounts payable & accrued expense increased from Dec. 2022 ($19.0 Mil) to Dec. 2023 ($28.5 Mil) and increased from Dec. 2023 ($28.5 Mil) to Dec. 2024 ($35.1 Mil).

AnaptysBio Accounts Payable & Accrued Expense Historical Data

The historical data trend for AnaptysBio's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Accounts Payable & Accrued Expense Chart

AnaptysBio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

15.79

10.42

19.04

28.46

35.05

AnaptysBio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															26.33	33.15	34.08	35.05	33.31

AnaptysBio Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

AnaptysBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

0HFQ:UK AN6:Germany

Address

10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121

Website

https://www.anaptysbio.com

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Executives

Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hollings Renton	director
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau	officer: General Counsel	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Dennis Mulroy	officer: Chief Financial Officer
Dennis M Fenton	director
Daniel Faga	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Hamza Suria	director, officer: President, CEO	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware	director	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei	officer: Chief Medical Officer	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121